Search
Ligand Pharmaceuticals Inc
LGNDAdd to Watchlist
274.880USD
+11.740+4.46%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
5.44BMarket Cap
35.82P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of Ligand Pharmaceuticals Inc is 8.75, ranking 9 out of 157 in the Pharmaceuticals industry. The average price target is 232.50, with a high of 275.00 and a low of 220.00.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
277.111
Target Price
+0.81%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
175
Total
6
Median
8
Average
Company name
Ratings
Analysts
Ligand Pharmaceuticals Inc
LGND
8
Biogen Inc
BIIB
38
Amgen Inc
AMGN
38
Eli Lilly and Co
LLY
35
AbbVie Inc
ABBV
34
Vertex Pharmaceuticals Inc
VRTX
34
1
2
3
...
35
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Ligand Pharmaceuticals Inc's expected revenue for the next quarter?
Ligand Pharmaceuticals Inc's expected revenue is 63.30M.
What is Ligand Pharmaceuticals Inc's price target?
Analysts forecast that Ligand Pharmaceuticals Inc's price target is USD 232.50, with the highest forecast at USD 275.00 and the lowest forecast at USD 220.00.
How have Ligand Pharmaceuticals IncLGND's recent earnings per share performed?
The market expectation was USD -0.67, while Ligand Pharmaceuticals IncLGND's earnings per share (EPS) for the previous quarter was USD 2.21. EPS for the next quarter is expected at USD 2.03.
What is the analyst rating for Ligand Pharmaceuticals Inc?
Based on the ratings of Ligand Pharmaceuticals Inc's stock from 8 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
